Biotechnology firm Jellagen, specializing in collagen, secures investment from Thai Union Corporate Venture Capital Fund.

Thai Union Group PCL has expanded its biotechnology interests by making an investment in a startup that extracts collagen from jellyfish. Jellagen, a prominent company in the field of advanced collagen biomaterials, is situated in Cardiff, UK. On December 8, 2022, Thai Union announced that its Corporate Venture Capital (CVC) Fund has participated in Jellagen's Series A funding round, which raised £8.7 million. The investment round saw participation from both strategic and financial partners. Established in 2015, Jellagen specializes in the development of jellyfish-derived collagen biomaterials, aiming to transform the field of regenerative medicine with its medical devices and culture applications. Preliminary clinical results have shown that Jellagen's Collagen Type 0, sourced from jellyfish, offers superior benefits over mammalian-sourced collagen, particularly in medical and healing contexts. The funds from this round will be directed towards further medical advancements of Collagen Type 0, promoting it as a sustainable option for treating skin conditions and for tissue reconstruction purposes. This investment by Thai Union paves the way for potential collaborative ventures in sourcing, processing, and integrating these innovations into Thai Union's product lineup. Caption: Jellagen’s Collagen Type 0 Scaffold (Credit: Jellagen) Thiraphong Chansiri, President and CEO of Thai Union, expressed enthusiasm about the partnership, highlighting Jellagen's leadership in jellyfish collagen research and its potential applications in medicine, cosmetics, and food and nutrition. He looks forward to potential collaborations in global research, development, and processing facilities. Thomas-Paul Descamps, CEO of Jellagen, celebrated the investment as a significant milestone, thanking Thai Union for their confidence in Jellagen's team and technology. He emphasized that the investment would bolster Jellagen's position as a leader in the global medical device and biomaterial market, ensuring the company's growth and the scalability of its manufacturing processes. Descamps also noted the investment's role in unlocking the vast potential of their Collagen Type 0 technology. Thai Union's CVC fund, established in 2019, focuses on alternative proteins, functional nutrition, biotechnology, and new food value chain technologies. The fund aims to partner with and support early-stage companies in these sectors, aligning with Thai Union's commitment to promoting healthy living and healthy oceans. More information about Thai Union’s Corporate Venture Capital Fund can be found on their website. --ENDS-- About Jellagen: Jellagen Ltd is a biotechnology firm dedicated to producing next-generation Collagen Type 0 for medical and scientific research. The company aims to commercialize marine-sourced collagen, leveraging its benefits over traditional mammalian sources and exploring therapeutic opportunities presented by Collagen Type 0. Founded in Cardiff, Wales, in 2015, Jellagen markets a range of Collagen Type 0 products for research, alongside developing clinical-grade formulations for therapeutic and medical device applications. The company's research is based on the work of Professor Andrew Mearns Spragg and focuses on sustainable biomaterial sourcing. About Thai Union: Thai Union Group PCL is a leading global seafood company, known for its high-quality, innovative seafood products. With a history spanning 45 years, Thai Union's brand portfolio includes international and Thai brands, catering to a global market. The company is committed to sustainability and innovation, recognized through its inclusion in the Dow Jones Sustainability Indices and the FTSE4Good Emerging Index. For media inquiries, please contact: - Adam Watts, Marketing Manager, Jellagen - Wiriyaporn Posayanonda, Head of External Communication, Thai Union - Markus Reber, European Communications Director, Thai Union